Potential Acquisition Update

RNS Number : 6845G

Tissue Regenix Group PLC

31 May 2017

 

Tissue Regenix Group plc

Potential Acquisition Update

Leeds, 31 May 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company, notes the recent dissolution of the temporary restraining order ("TRO") issued by Bexar County District Court against CellRight Technologies, LLC ("CellRight"), a US regenerative medicine business based in San Antonio, Texas, in relation to a potential sale of CellRight to Tissue Regenix. Tissue Regenix confirms that it remains in discussions with CellRight regarding a possible acquisition of CellRight by Tissue Regenix.  There can be no certainty at this stage that the discussions between the Group and CellRight will lead to an acquisition.

A further announcement will be made when appropriate.

This announcement contains inside information.

For more Information:

Tissue Regenix Group plc Caitlin Pearson                                 Corporate Communications Director	Tel: [phone]
Jefferies International Ltd Simon Hardy / Harry Nicholas	Tel: [phone]
FTI Consulting Brett Pollard / Mo Noonan	Tel: [phone]

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

 Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

 In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.

 

END

 

 

ACQWGUPAAUPMURG